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Endovenous laser ablation: Venous outcomes and
thrombotic complications are independent of
the presence of deep venous insufficiency
Brian S. Knipp, MD,a Susan A. Blackburn, RN, MBA,a Jess R. Bloom, RVT,a Elaine Fellows, NP,a
William LaForge, RN,a John R. Pfeifer, MD,a David M. Williams, MD,b and
Thomas W. Wakefield, MD,a for the Michigan Venous Study Group,* Ann Arbor, Mich
Objective: We hypothesize that endovenous laser ablation (EVA) therapy is equally successful in improving venous
insufficiency symptoms in patients with or without deep venous insufficiency (DVI).
Methods: From January 2005 through August 2007, EVA of the great saphenous vein (GSV) was attempted in 364
patients (460 limbs) with symptomatic GSV reflux. The GSV was successfully cannulated and obliterated in all but 17
limbs. EVAwas performed alone in 308 limbs (69.5%) and with phlebectomy or perforator ligation (EVAP) in 135 limbs
(30.5%). Venous clinical severity scores (VCSS) were recorded preoperatively and at 30, 90, 180, and 360 days
postoperatively. Patients were classified as those with or without DVI based on duplex imaging valve closure times at the
common femoral vein (CFV) and popliteal vein (PV). In a subset of 181 patients undergoing EVA therapy in the
operating room, perioperative thrombosis prophylaxis was administered based on a risk-stratification protocol. Patients
were assessed with direct end points (VCSS) and indirect end points (vein occlusion rates).
Results: Successful performance of EVA led to complete saphenous vein ablation in 99.8% at 1 month and 95.9% at 1 year.
Median VCSS preoperatively was 6 (interquartile range, 5-8), generally decreasing over all time points to 4 (interquartile
range, 2-5) beyond 360 days (P < .001). Male gender was independently associated with greater improvement in scores
with time (P  .019). Changes in VCSS and duration of vessel occlusion were equivalent regardless of DVI for both
isolated EVA and EVAP. For EVAP, the true deep venous thrombosis (DVT) rate was 2.2%, whereas for isolated EVA,
the rate was 0% (P .028); the rate of saphenofemoral thrombus extension was 5.9% for EVAP vs 7.8% for isolated EVA
(P  .554). The use of risk-adjusted heparin prophylaxis in patients undergoing EVAP did not have a significant effect
on thrombotic complications. There were no differences in true DVT, thrombus extension, or superficial thrombophle-
bitis between patients with or without DVI. Performance of concomitant phlebectomy, DVI, gender, and age had no
effect on the duration of vessel occlusion.
Conclusion:EVA produces successful ablation and is associated with sustained improvement in VCSS. These outcomes are
independent of the presence of DVI. Finally, the use of a risk-adjusted thrombosis prevention protocol had no effect on
the rate of superficial thrombus extension from EVA or EVAP in patients undergoing general anesthesia. ( J Vasc Surg
2008;48:1538-45.)Superficial venous insufficiency is a major health prob-
lem leading to symptomatic lower extremity venous vari-
cosities in 20% of the United States population.1 Left
untreated, superficial venous reflux may progress to more
severe disease, with signs and symptoms including swelling,
aching, skin discoloration, and venous ulceration. The tra-
ditional management of superficial venous insufficiency has
been ligation of the great saphenous vein (GSV) or the
small saphenous vein (SSV), or both, with or without
stripping of the vein and removal of the superficial venous
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1538varicosities. The interaction of superficial and deep venous
insufficiency (DVI), however, has been evaluated in only a
limited fashion in the literature,2 and to our knowledge, no
evaluation has been done of the specific effect of DVI on
the outcomes of saphenous ablation.
Endovenous laser ablation (EVA) of the saphenous
vein has become an accepted alternative to ligation and
stripping. This technique is equivalent to surgical ligation
and vein stripping in terms of clinical symptom resolution
and superior in terms of postoperative morbidity in several
trials.3-5 In many centers endoluminal ablation occurs in an
outpatient setting under local anesthesia only.
In this report we present our 2-year experience with
EVA of the GSV. We hypothesize that EVA is effective in
alleviating symptoms of superficial venous insufficiency,
irrespective of the presence or absence of deep venous
involvement.
METHODS
Data source. Patients presenting with varicose veins
or other manifestations of superficial venous insufficiency
(with or without DVI) were offered treatment. Laser abla-
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and outpatient surgery center (810-nm Endovenous Laser
Treatment [EVLT] system, Diomed Inc, Andover, Mass)
or in the interventional radiology suite (810-nm Vari-Lase
system, Vascular Solutions, Minneapolis, Minn), depend-
ing on patient demographics, was attempted in 364 pa-
tients and 460 limbs from January 2005 through August
2007. Procedures for patients who needed concomitant
phlebectomy (EVAP) or who desired general anesthesia
were performed in the operating room. Patients were pro-
spectively entered into a quality assurance database and
reviewed retrospectively using the venous reporting stan-
dards guidelines.6 This study was approved by the Institu-
tional Review Board of the University of Michigan (IRB
approval number HUM00005768).
Duplex testing. Patients underwent a full duplex ul-
trasound evaluation from groin to knee to rule out acute
deep venous thrombosis (DVT). Valve closure times were
measured at the level of the GSV 1 cm distal to the
saphenofemoral junction, the common femoral vein (CFV)
2 cm distal to the saphenofemoral junction, and the popli-
teal vein (PV). At all levels, imaging was performed in the
sagittal plane, and the angle was corrected.
Reverse flow in the GSV and CFV were measured
during a Valsalva maneuver, and reverse flow in the PV was
measured during above knee proximal compression. Ac-
cording to University of Michigan Diagnostic Vascular
Laboratory protocol, valve closure times 500 millisec-
onds were considered abnormal (modified from Labropou-
los et al).7
Reflux in either the CFV or the PV was considered DVI
for the purposes of this study. Perforator incompetence was
identified with proximal compression and distal augmenta-
tion related to the perforator, again using a valve-closure
time of 500 milliseconds as abnormal. Postoperatively,
patients underwent a full duplex ultrasound venous evalu-
ation documenting flow and the presence or absence of
thrombosis, but not reassessing reflux.
EVA procedure. Patients were treated in three set-
tings: an outpatient clinic, an interventional radiology suite,
or in the operating room under general anesthesia, usually
with concomitant phlebectomy (EVAP). Approximately
200 mL of tumescent anesthesia (450 mL of normal saline
mixed with 50 mL of 1% lidocaine with epinephrine and 15
mL sodium bicarbonate) was infused around each GSV by
hand or in the latter part of the series by a Klein pump (HK
Surgical, San Clemente, Calif).
The leg was cannulated just above the knee, if possible, or
at a level where the saphenous vein was of an adequate size.
After placement of the laser catheter, the vein was treatedwith
14 W of continuous energy as the laser catheter was with-
drawn at 1 mm/second for the first 100 seconds, followed by
2.5mm/second until the laser was 1 cm from the skin surface.
Ablation was initiated either distal to the first tributary of the
GSV in the groin or 2 cm from the saphenofemoral junction.
External compression with the ultrasound probe was used,
and the patient was placed in 30° Trendelenburg position
during pullback.If concomitant phlebectomy was performed, stab inci-
sions were made and veins removed with specially designed
crochet hooks (Cardinal Health, Ann Arbor, Mich). All
wounds were closed with SteriStrips (3M Corp, St. Paul,
Minn).
Postoperatively, patients’ legs were dressed with a non-
stretch Comprilan dressing (Beiersdorf Inc, Hamburg,
Germany), a stretch ACE wrap (Hartman-Conco, Inc,
Rock Hill, SC), or a combination of both. Early in the
experience, patients were instructed not to ambulate the
evening of the operation; later they were encouraged to
ambulate postoperatively. Compression bandaging was left
in place for 48 hours, followed by daily bandaging until
approximately 1 week postoperatively. At this time, patients
were placed back in thigh-length compression stockings,
with 30 to 40 mm Hg pressure preferred.
Demographic and clinical information. We re-
corded gender, side of procedure, date of operation, and
type of operation (EVA or EVAP). Preoperative basic
CEAP assessment8 was determined from clinic notes and
venous reflux measurements.
Complications. We evaluated the rates of true DVT,
thrombus extension from the saphenofemoral junction into
the deep system, pulmonary embolism, superficial throm-
bophlebitis, neovascularization, cellulitis, fluid collections
requiring drainage procedures, and bruising. We specifi-
cally differentiated thrombus extension from the saphe-
nofemoral junction into the deep system from true DVT
based on the ultrasound report. Bruising was categorized as
absent, mild, or moderate based on subjective assessment
by the examining clinician; no cases of severe bruising were
noted. No specific bruising scale was used.
Prevention of DVT. We instituted a policy in our
main operating room of preoperative DVT risk factor as-
sessment9,10 and administration of preoperative and post-
operative unfractionated or low-molecular-weight heparin
according to on overall risk. Patients underwent general
anesthesia in most cases. Patients with up to two risk factors
received no prophylactic heparin. Those with three or four
risk factors received one dose of 5000 U of unfractionated
heparin or 30mg of Lovenox (Sanofi-Aventis, Bridgewater,
NJ) within 60 minutes of the operation. Those with five or
more risk factors received the perioperative dose of prophy-
lactic unfractionated heparin or Lovenox as well as prophy-
lactic Lovenox for 1 week postoperatively (based on our
own protocol). This change went into effect May 9, 2006.
All patients whose procedures were performed in the oper-
ating room after this time received the DVT prevention
protocol. We evaluated thrombotic complications in the
subset performed in our operating room before and after
this protocol was implemented.
Venous clinical severity scoring. At each clinic visit,
the examiner performed a venous clinical severity scoring
(VCSS) assessment11 (maximum, 30 points). These scores
were assessed preoperatively as well as postoperatively at
days 0 to 30, 30 to 90, 90 to 180, 180 to 360, and 360.
Imaging follow-up. Duplex ultrasound evaluation of
the superficial and deep venous systems was performed at
s.
A.
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nous vein ablation. We defined a vessel as being reopened
and a treatment failure if there was recanalization from the
laser insertion site to the saphenofemoral junction.
Statistical analysis. All categoric comparisons were
evaluated using 2 analysis, ordinal variables using nonpara-
metric tests, and continuous variables using the t test.
Duration of venous occlusion by ultrasound evaluation was
assessed by life-table analysis. Analysis of factors predictive
of late failure was performed using Kaplan-Meier and Cox
proportional hazards modeling. Analysis of the interaction
of specific variables with the rate of change of VCSS was
performed by applying a fixed-effects model to analyze
intravariable and intervariable contributions to variation.
Statistical calculations were done using SPSS 11.0.1 (SPSS,
Inc., Chicago, Ill) and STATA 10.0 (StataCorp, College
Station, Tex) software.
RESULTS
Demographic information. EVA was attempted in
364 patients and 460 limbs. The average length of
follow-up was 7.4  6.2 months (range, 1 week-35.6
months); two patients were lost to follow-up. Treatment
occurred in the operating room for 181 limbs (39.4%), at
an outpatient surgery center for 231 (50.2%) and in the
radiology suite for 48 (10.4%).
There were no major differences between the patients
with DVI and without DVI (Table I). Average age was
50.6  12.2 years for patients with DVI compared with
51.1  12.2 years for those without DVI (P  .671).
Similar percentages were women (77.5% vs 78.0% for those
with and without DVI, respectively, P  .99) and under-
went bilateral treatment (10% vs 8.3%, P  .723). More
patients with DVI had treatment of a right-sided saphenous
vein than those without DVI (51.4% vs 40.9%, P  .048).
The number of DVT risk factors was similar, with a median
of four factors (interquartile range, 3-6) for patients with
DVI vs four (interquartile range, 3-7; P .578) for patients
without DVI. In addition, the number of stab incisions for
EVAPwas similar, with a median of 30 (interquartile range,
24-37) for patients with DVI vs 26 (interquartile range,
21-31; P  .097) for patients without DVI.
Seventy-four cases were performed in the operating
room before the initiation of the DVT prevention protocol
Table I. Demographics of patients with and without deep
Variable D
Age, average  SD (range), y 50.6  12
Female, No. (%) 241 (7
DVT risk factors, median (IQR) No. 4 (3
Right side, No. (%) 160 (5
Bilateral EVLT,a same setting, No. (%) 31 (1
EVAP stabs, median (IQR) No.b 30 (2
DVI, Deep venous insufficiency; EVA, endovenous laser ablation; EVAP, e
aEVLT (Endovenous Laser Treatment) system, Diomed Inc, Andover, Mas
bData are for patients who underwent phlebectomy concomitantly with EVand 107 cases after initiation of the protocol. Two or fewerrisk factors were present in 12 patients (11.2%), and there-
fore they received no prophylaxis; 42 (39.3%) had three or
four risk factors and were treated with a single perioperative
dose of unfractionated heparin or Lovenox; and 45 (42.1%)
had five or more risk factors and were therefore treated with
a perioperative dose of unfractionated heparin or Lovenox
as well as a week postoperatively. Risk factor data were
missing for eight patients (7.4%).
The distribution of the maximum CEAP clinical class
per patient successfully treated was as follows: C1, 1.6%;
C2, 52.6%; C3, 15.6%; C4, 20.1%; C5, 7.4%; and C6, 2.7%.
A total of 436 limbs (98.4%) were treated for symptomatic
disease; those without symptoms were treated either for
severe varicosities that interfered with compression therapy
compliance or for recurrent thrombophlebitis. Etiology
was primary in 421 limbs (95.0%), secondary in 18 (4.1%),
and congenital in four (0.9%). Reflux was isolated to the
superficial system only in 132 limbs (29.8%) and involved
the superficial and deep system in 311 (70.2%). Reflux of
the common femoral vein valve was observed in 302 limbs
(68.2%), the PV valve in 71 (16.0%), and in both the CFV
and PV in 61 (13.8%).
The average energy delivered per ablation was 2201.4 
542.9 J. The average lineal endovenous energy density per
limb was 80.7  14.3 J/cm.
Overall clinical outcomes. EVA was performed suc-
cessfully in all but 17 limbs, for a technical success rate of
96.3%. In seven limbs, the saphenous vein was in spasm and
a catheter could not be advanced up to the saphenofemoral
junction. In five limbs the micropuncture needle could not
access the vein, in four the wire could not be introduced,
and in one the catheter could not be placed due to venous
webs. Four immediate technical failures occurred in the
operating room, and all were immediately converted to
open ligation and stripping of the saphenous vein. In the
other venues, repeat procedures or referral for surgical
approaches was necessary.
The overall rate of vessel occlusion was 99.8% at 1
month, 98.7% at 6 months, 95.9% at 12 months, 94.8% at
18 months, and 91.4% at 24 and 30 months.
Of the 11 recanalizations, two patients were asymp-
tomatic and treated conservatively with compression stock-
ings, six underwent open saphenous ligation and stripping,
and three underwent repeat EVA. There was no difference
ous insufficiency
No DVI P
-81) 51.1  12.2 (27-90) .671
103 (78.0) .99
4 (3-7) .578
54 (40.9%) .048
11 (8.3%) .723
) 26 (21-31) .097
nous laser ablation with phlebectomy; IRQ, interquartile range.ven
VI
.2 (16
7.5)
-6)
1.4)
0)
4-37
ndovein average lineal endovenous energy density between ves-
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80.8 14.3 J/cm, P .511). However, the vein size at the
saphenofemoral junction was larger in vessels that recana-
lized (0.99  0.34 vs 0.75  0.27 cm, P  .042), and the
same trend was seen at the site of entry (0.67  0.27 vs
0.52  0.18 cm, P  .085). Cox proportional hazards
modeling failed to identify any patient-specific variables
related to the duration of occlusion.
VCSS scores improved significantly with time (P 
.001 via Kruskal-Wallis test). Median VCSS decreased at all
time points, from a preoperative score of 6 (interquartile
range, 5-8) to 4 (interquartile range, 2-5) beyond 360 days
(Table II). Men tended to have more rapid improvement in
their VCSS than women (P  .019).
In our series, there were 3 limbs with true DVT (0.7%),
32 with saphenofemoral thrombus extension (7.2%), 11
with superficial thrombophlebitis (2.5%), and 1 pulmonary
embolism (0.2%) occurred that was associated with a saphe-
nofemoral thrombus extension and was not a true DVT.
Bruising was assessed at the first postoperative visit
(postoperative day 4 at the outpatient surgery center and
postoperative day 7 at the main hospital and radiology
center) by the clinical examiner at follow-up. Data were
available for 303 limbs (67.5%). Bruising was minimal in 48
limbs (15.9%), moderate in 77 (25.4%), and no bruising
was apparent in 178 (58.7%).
There were 9 cases (2.0%) of cellulitis in patients’ limbs, 4
(0.9%) of postoperative fluid collections requiring further
intervention, 4 (0.9%) of neovascularization and perivenous
inflammation, and 2 (0.5%) of paresthesias.
The role of DVI. By Kaplan-Meier analysis, there was
no significant difference in the duration of vessel occlusion
in patients with or without DVI (P  .117, see Fig 1).
Using a fixed-effects model, we found that DVI had no
effect on the rate of change of the VCSS (P .572; Fig 2).
There were no significant differences in the rates of
DVT, saphenofemoral thrombus extension, superficial
thrombophlebitis, paresthesias, or bruising when compar-
ing limbs in the presence or absence of DVI.
The role of concomitant phlebectomy. EVA was the
sole procedure in 321 limbs; Concomitant procedures in
135 limbs (29.6%) were phlebectomy in 98 (21.4%) or
perforator ligation in 37 (8.2%). The average number of
stab incisions was 31  12 (range, 7-73). There were no
differences in the rate of change of VCSS or the duration of
vessel occlusion based on performance of EVAP (data not
shown).
When concomitant phlebectomy or perforator inter-
ruption was performed with EVA, the rate of true DVT
increased (2.2% vs 0%, P  .028), but no difference was
found in saphenofemoral thrombus extension (5.9% vs
7.8%, P  .554) or superficial thrombophlebitis (4.4% vs
1.6%, P .097). Of note, in all cases of thrombophlebitis in
which concomitant EVAP was performed, the thrombo-
phlebitis was related to the phlebectomy sites, not to the
ablated saphenous vein. The rates of paresthesias or cellu-
litis did not differ, but the rate of bruising was substantiallyhigher in cases of EVAP (P  .001), related to the phle-
bectomy itself.
The role of the DVT prevention protocol. Before
Table II. Venous clinical severity scores by component
at the preoperative visit and postoperatively at 1 month
and 1 year
Variable
Initial
screening
(n  322),
No. (%)
Post-op screening, No. (%)
1 month
(n  319)
1 year
(n  104)
Pain
None 106 (32.9) 116 (36.4) 80 (76.9)
Occasional 87 (27.0 77 (24.1) 15 (14.4)
Daily 97 (30.1) 58 (18.2) 6 (5.8)
Daily with meds 32 (9.9) 68 (21.3) 3 (2.9)
Varicose veins
None 5 (1.6) 72 (22.6) 35 (33.7)
Few 56 (17.4) 164 (51.4) 56 (53.9)
Multiple 151 (46.9) 64 (20.1) 8 (7.7)
Extensive 110 (34.2) 19 (6.0) 5 (4.8)
Venous edema
None 103 (32.0) 209 (65.5) 84 (80.8)
Evening only 111 (34.5) 59 (18.5) 13 (12.5)
Afternoon 56 (17.4) 21 (6.6) 4 (3.8)
Morning 52 (16.1) 30 (9.4) 3 (2.9)
Skin pigmentation
None 199 (61.8) 240 (75.2) 83 (79.8)
Limited, old 64 (19.9) 45 (14.1) 16 (15.4)
Diffuse, recent 48 (14.9) 24 (7.5) 3 (2.9)
Wider, recent 11 (3.4) 10 (3.1) 2 (1.9)
Inflammation
None 304 (94.4) 302 (94.7) 102 (98.1)
Mild cellulitis 10 (3.1) 12 (3.8) 1 (1.0)
Moderate cellulitis 7 (2.2) 4 (1.3) 1 (1.0)
Severe cellulitis 1 (0.3) 1 (0.3) 0 (0)
Induration
None 307 (95.3) 292 (91.5) 103 (99.0)
Focal 5 cm 5 (1.6) 19 (6.0) 1 (1.0)
Medial leg 8 (2.5) 6 (1.9) 0 (0)
Diffuse leg 2 (0.6) 2 (0.6) 0 (0)
Active ulcers, No.
0 314 (97.5) 314 (98.4) 102 (98.1)
1 7 (2.2) 4 (1.3) 2 (1.9)
2 0 (0) 0 (0) 0 (0)
2 1 (0.3) 1 (0.3) 0 (0)
Ulcer duration, mon
0 315 (97.8) 314 (98.4) 102 (98.1)
3 2 (0.6) 2 (0.6) 0 (0)
3-12 3 (0.9) 1 (0.3) 1 (1.0)
12 2 (0.6) 2 (0.6) 1 (1.0)
Active ulcer size, cm
0 316 (97.8) 314 (98.4) 102 (98.1)
2 5 (1.5) 4 (1.3) 1 (1.0)
2-6 2 (0.6) 1 (0.3) 1 (1.0)
6 0 (0) 0 (0) 0 (0)
Compression therapy
None 129 (39.9) 35 (11.0) 20 (19.0)
Intermittent 40 (12.4) 5 (1.6) 14 (13.3)
Most days 60 (18.6) 26 (8.2) 31 (29.5)
Fully compliant 94 (29.1) 252 (79.2) 40 (38.1)
Median VCSSa 6 (5-8) 6 (4-7) 3 (2-5)
IQR, Interquartile range; VCSS, venous clinical severity score.
aThese values are mean (IQR).the initiation of the protocol, there was one case (1.4%) of
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sion, and three cases (4.2%) of superficial thrombophlebitis.
In procedures performed after the protocol went into ef-
fect, there were two cases (1.9%) of DVT, eight (7.5%) of
saphenofemoral thrombus extension, and five (4.7%) of
Fig 1. No difference was identified in duration of vess
compared with limbs without DVI (P  .117).
Fig 2. Box and whisker plots show that by fixed-effects modeling,
the presence of deep venous insufficiency (DVI) had no effect on
the rate of total venous clinical severity scores (VCSS) improve-
ment (P  .572). The horizontal line in the middle of each box
indicates the median; the top and bottom borders of the box mark
the 75th and 25th percentiles, respectively. The whiskers mark the
90th and 10th percentiles.superficial thrombophlebitis. The rates of these complica-tions were not statistically different between the two treat-
ment groups.
Correlation of recannalization to clinical outcome.
To assess the relevance of recanalization as a valid outcome,
a fixed-effects model was applied to the VCSS vs recanali-
zation. The rate of change of the VCSS was significantly
correlated with recanalization, with less improvement
noted in VCSS (P  .04) in the presence of recanalization
(Fig 3).
DISCUSSION
Venous insufficiency is a common disorder leading to a
significant health burden for millions of Americans. Risk
factors for varicose veins include age, female gender, family
history of varicosities, obesity, and occupational factors.12
Visible venous varicosities occur in 10% to 15% of men and
20% to 30% of women.1,13 Yet, the symptoms of venous
insufficiency, including leg heaviness, aching, cramping,
and swelling, are often under-recognized by patients and
primary care physicians. Treatment of superficial venous
reflux is associated with significant improvements in symp-
tomatic complaints as well as improved quality of life
scores.4-5,14-16
Traditional management of superficial reflux has been
open ligation and stripping of the GSV. The principles of
management are the removal of the hydrostatic forces by
ligation of the incompetent saphenofemoral junction and
removal of the saphenous trunk. However, this procedure
is associated with significant morbidity and postoperative
clusion in limbs with deep venous insufficiency (DVI)el ocpain. Attempts to limit the procedure to simple ligation of
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nous varicosities, or ligation and sclerotherapy have been
characterized by unacceptably high recurrence rates.17-19
Recurrence is problematic even in patients undergoing
saphenous stripping alone. In a 2007 study, Kostas et al20
documented 23% recurrence and a 16% saphenous nerve
injury rate in patients undergoing stripping of the GSV. In
addition, although the traditionally accepted rate of DVT
from open surgical management of superficial venous in-
sufficiency is 0.15% to 1.8%,21 van Rij et al22 documented a
5.3% rate of DVT in a prospective study.
In 1999 Boné23 first published the technique of EVA
of the saphenous vein. In 2001 Navarro et al24 published
the first report in the English literature of 40 saphenous
veins treated with an 810-nm laser and documented no
recanalizations with a mean follow-up of 4.2 months. In
the same year,Min et al25 documented a 99% occlusion rate
in 90 saphenous veins treated with EVA. A randomized
trial comparing EVA with open ligation and stripping doc-
umented similar results in quality of life improvement and
VCSS, and significantly decreased pain in patients treated
with endoluminal ablation.5 In addition, the VCSS has
been recently validated in a study using the technique of
radiofrequency ablation.26
There has been concern that thromboembolic compli-
cations may be higher with endoluminal techniques be-
cause the practice of flush ligation in the open procedure
cannot be duplicated.27 However, in the five largest studies
of EVA in the literature to date, including a total of 3720
limbs, the incidence of DVTwas 0.027% (1 in 3720 limbs),
pulmonary embolism was 0.038% (1 in 2644 limbs), and
Fig 3. Box and whisker plots show that by using fixed-effects
modeling, there was significantly less improvement (P  .04) of
venous clinical severity scores (VCSS) in limbs with complete vessel
recanalization compared with vessels that remained occluded. The
horizontal line in the middle of each box indicates the median; the
top and bottom borders of the box mark the 75th and 25th percenti-
les, respectively. The whiskers mark the 90th and 10th percentiles.superficial thrombophlebitis was 5.5% (91 in 1654limbs).28-32 It is unclear from the descriptions of these
studies whether there were no extensions of thrombus from
the saphenofemoral junction, if the one recorded DVT was
such a thrombus, or whether this entity was even systemat-
ically evaluated.
Smaller series that have focused specifically on saphe-
nofemoral thrombus extension have documented rates of
2.3% to 7.7%.27,33 In our study the true DVT rate was
0.7%, the rate of saphenofemoral thrombus extension was
7.2%, the pulmonary embolism rate was 0.2% (1 case), and
the superficial thrombophlebitis rate was 2.5%. The institu-
tion of a risk-based prophylaxis protocol had no effect on
these rates. Some investigators have reported use of 5 to 7
days of postoperative low-molecular-weight heparin,33
whereas others have reported no benefit to prophylaxis in
high-risk patients, which would support our findings.34-36
At present there is no consensus on the management of
thrombus extensions into the deep venous system. Johnson
and McLafferty37 recommend low-molecular-weight hep-
arin, followed by a 6-week course of Coumadin (Bristol-
Myers Squibb, Princeton, NJ), with a target international
normalized ratio of 2.0 to 3.0. It is our practice to treat
these patients with 1 week of low-molecular-weight hepa-
rin and a repeat duplex ultrasound study. In almost all cases,
the thrombus extension has resolved and no further treat-
ment is required.
One of the principal findings in this study was that DVI
was not a barrier to the safe and effective performance of
EVA for the GSV.We found that VCSS improved, irrespec-
tive of the presence or absence of DVI. The VCSS has been
suggested to be a good means of evaluating clinical im-
provement after saphenous ablation.26 We also recorded a
revised VCSS, eliminating the compression component,
because many patients were inadequately treated with com-
pression preoperatively or were noncompliant. However,
the findings were identical to those for the total VCSS, and
therefore we have not included these data.
There have been suggestions in the literature that DVI
may be secondary to superficial reflux, and therefore surgi-
cal correction of saphenous reflux should decrease the
degree of deep venous reflux.38 We cannot support or
refute these statements, because we did not routinely ob-
tain repeat postablation reflux studies. Hach-Wunderle
et al2 presented an analysis of open surgical vs endovenous
management of superficial venous insufficiency and its role
in the development of secondary deep insufficiency, sug-
gesting that removal of the superficial varicosities is suffi-
cient in mild forms of the disease, but crossectomy and
stripping of the saphenous trunk were required for severe
disease. Sharif et al39 documented excellent wound healing
in patients with chronic venous insufficiency and C5 or C6
level disease after EVA, yet patients with DVI were specif-
ically excluded from analysis.
We have documented effectiveness of EVA of the GSV
in our patients, with vessel occlusion rates of 98.7% at 6
months and 91.4% at 30 months. This is comparable with
other studies that have documented occlusion rates of
JOURNAL OF VASCULAR SURGERY
December 20081544 Knipp et al95.7% to 98.5% at 6 months and 93.4% to 97.8% at 24
months (Table III).28-32
One of the limitations of this study is that it was
retrospective and nonrandomized. Patients were chosen for
EVA or EVAP based on the clinician’s assessment of vein
size and whether saphenous ablation alone would be suffi-
cient treatment for the varicosities.
Second, this database included three different opera-
tors at three different sites. However, although we did not
include these data in the results, we found no significant
differences in duration of vessel occlusion or complication
rate based on site or operator.
Third, follow-up assessment was done by the partici-
pating clinicians who were not blinded to the procedure
performed. However, VCSS were obtained by multiple
providers who were not aware of preoperative or prior
scores.
Finally, our definition of DVI was based on an isolated
evaluation of the CFV and PV using a 500-millisecond
cutoff for valve-closure time.
One potential criticism of the evaluation of recanaliza-
tion rates as a clinical end point is that it is not clear that this
event is associated with worse outcomes or recurrence of
symptoms. In one study, greater than 40% of recanalized
saphenous veins exhibited symptomatic resolution.40 Yet,
when we applied a fixed-effects model to the rate of change
of VCSS, we found that although symptomatic improve-
ment was present, it was diminished compared with limbs
without recanalization. Therefore, we consider recanaliza-
tion to be a valid surrogate endpoint of efficacy.
CONCLUSION
In our experience the performance of EVA was associ-
ated with sustained vessel occlusion and significant im-
provements in clinical severity assessments regardless of
DVI. We also found that the use of a prevention protocol
based on risk factors had no effect on the rate of thrombotic
complications.
We would like to acknowledge the assistance of Justin
Dimick, MD, in the statistical analysis of this work.
APPENDIX
The Michigan Venous Study Group includes the au-
thors and Gayle Adams, PA, Eric Ferguson, MD, Peter K.
Table III. Comparative table of studies in the literature fo
First author, year No. 1 3
Min,28 2003 499 98.0 99.3
Agus,29 2006 1076 . . . . . .
Ravi,30 2006 990 96.7 . . .
Desmyttère,31 2007 511 98.4 . . .
Theivacumar,32 2008 644 . . . 96.0
Present study 449 99.8 . . .Henke, MD,Michael Hong, MD, and FarahMansoor, BS,all from the Section of Vascular Surgery at the University of
Michigan, Ann Arbor.
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